side-to-side functional end anastomosisKono-S analstomosis
side-to-side functional end anastomosis: type of anastomosis
Kono-S analstomosis: antimesenteric anastomosis
Study summary
This study proposes a randomized prospective study comparing the Kono-S anastomosis to the standard side-to-side anastomosis.This will be a multi-center randomized prospective trial. Patients with Crohn's ileitis or Crohn's ileocolitis requiring resection will be randomized to undergo either the Kono-S anastomosis or the side-to-side functional end anastomosis.
Eligibility
Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria:
1. Patients with Crohn's ileitis or ileocolitis requiring initial surgical resection.
2. Age of 18 years and older, male and female
3. All Phenotypes of Crohn's diisease will be included: nonpenetrating (B1), stricturing (B2), and penetrating (fistulating) (B3), according to the Vienna classification
4. The patients can be on any medications coming into surgery, including prior anti- tumor necrosis factor(TNF) therapy.
Exclusion Criteria:
1. Patients under 18 years of age
2. Patients with recurrent Crohn's
3. Pregnant patients
4. Patients with more than one non-contiguous site of active disease, thus requiring multiple resections or additional bowel sparing procedures at the time of surgery.
5. Patients with Crohn's disease extending to the cecum and ascending colon
6. Patients who will need preventive postoperative medical treatment
7. Patients that need change of surgical procedure as per the surgeon at the time of the intraoperative abdominal evaluation.
Primary outcome measure(s)
Post-operative endoscopic remission of Crohn's disease between 3 and 6 months after surgery — 3-6 months after surgery Endoscopic remission with a modified Rutgeerts score between 3 and 6 months in order to determine if the Kono-S procedure is more likely to prevent post-operative recurrence of Crohn's disease compared with the side-to-side functional end anastomosis. Endoscopic remission is defined as a modified Rutgeerts score of 0, 1, or 2a at 3-to-6 months post-procedure colonoscopy.
Number of subjects with surgical recurrence at 60 months — 60 months after surgery Number of anastomoses in need of surgical revision for Crohn's disease recurrence after the initial index surgery.
Number of subjects with surgical recurrence at 120 months — 120 months after surgery Number of anastomoses in need of surgical revision for Crohn's disease recurrence after the initial index surgery.
Mucosal Healing GHS — 60 months after surgery Mucosal Healing from colonoscopy biopsies using the modified Global Histology Activity Score (Modified) score between the groups. Global Histology Activity Score (GHAS) is a widely used tool that grades biopsies of the ileum and colonic segments. The score has 8 domains and includes the presence of architectural changes, degree of chronic, neutrophilic and eosinophilic inflammatory infiltration in lamina propria, presence of intraepithelial neutrophils, epithelial damage, mucosal defects, presence of granulomas, and the extent of inflammation (proportion of biopsy specimens affected). Each domain is scored independently, and the total score is the sum of all individual scores, ranging from 2 (being the lowest meaning no histological activity) to 16 (being the highest meaning high histological disease activity).
Mucosal Healing IBD-DCA — 60 months after surgery Mucosal Healing from colonoscopy biopsies using The Inflammatory Bowel Disease-Distribution, Chronicity, Activity \[IBD-DCA\] score between the groups. The score is validated and has 3 domains: 1) Distribution of the disease; 2) Chronicity of the disease; and 3) Activity of the disease. Each domain of the IBD-DCA is scored as one of 0 (normal), 1 (mild), or 2 (moderate to severe) based on the presence of established histological findings and the domains are separately reported.
Distribution \[D\] 0=Normal
1. \< 50% of tissue affected per same biopsy site
2. ≥ 50% of tissue affected per same biopsy site Chronic features \[C\] 0=Normal
1=Crypt distortion and/or mild lymphoplasmacytosis 2=Marked lymphoplasmacytosis and/or marked basal plasmacytosis Activity features \[A\] 0=Normal
1. Two or more neutrophils in lamina propria in one high-power field \[HPF\] and/or intraepithelial neutrophils \[any number\]
2. Crypt abscesses, erosions, ulcers
Surgical Pathology Margins — at surgery Histological evaluation of the surgical pathology margin evaluation for presence or absence of disease
Trial sites (15)
Facility
City
Region
Status
Massachusetts General Hospital
Boston
Massachusetts
Terminated
Weill Cornell Medical College
New York
New York
Recruiting
University of Oklahoma
Oklahoma City
Oklahoma
Terminated
Baylor Scott & White Research Institute
Dallas
Texas
Terminated
Baylor College of Medicine
Houston
Texas
Terminated
University of Washington Medical Center
Seattle
Washington
Terminated
University Clinics Gasthuisberg Herestraat
Leuven
Belgium
Recruiting
Helsinki University Hospital
Helsinki
Helsinki
Terminated
Universitätsklinik Würzburg
Würzburg
Wurzburg
Recruiting
Charité Campus Benjamin Franklin
Berlin
Germany
Recruiting
Theresien Hospital and St. Hedwigs Clinic gGmbH
Mannheim
Germany
Recruiting
Azienda Ospedaliero-Universitaria Careggi
Florence
Florence
Recruiting
Humanitas University Hospital
Rozzano
Milan
Recruiting
Policlinico University Hospital
Naples
Italy
Recruiting
Hospital Universitario Vall d'Hebron
Barcelona
Barcelona
Terminated
More Weill Medical College of Cornell University trials in Germany
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.